# Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects

> **NCT06265012** · PHASE1 · COMPLETED · sponsor: **Public Health Vaccines LLC** · enrollment: 36 (actual)

## Conditions studied

- Marburg Virus Disease

## Interventions

- **BIOLOGICAL:** PHV01
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06265012
- **Lead sponsor:** Public Health Vaccines LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-05
- **Primary completion:** 2024-09-23
- **Final completion:** 2024-09-23
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06265012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06265012, "Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06265012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*